½ÃÀ庸°í¼­
»óǰÄÚµå
1609556

ÀÚ°¡ÁÖ»ç±â ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® : Á¦Ç°º°, »ç¿ë¼ºº°, ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)

Self-injection Devices Market Size, Share & Trends Analysis By Product (Auto Injectors, Pen Injectors), By Usability (Disposable, Reusable), By Application (Cancer, Autoimmune Disorders, Hormonal Disorders), By Region, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÀÚ°¡ÁÖ»ç±â ½ÃÀå ¼ºÀå ¹× µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, ¼¼°è ÀÚ°¡ÁÖ»ç±â ½ÃÀå ±Ô¸ð´Â 2025³âºÎÅÍ 2030³â±îÁö 10.31%ÀÇ CAGRÀ» ±â·ÏÇϸç 2030³â±îÁö 405¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ȯÀÚ ¼ö Áõ°¡, ¸¸¼ºÁúȯ À¯º´·ü Áõ°¡, ÷´Ü ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ ³ôÀº äÅ÷ü µîÀº ÀÚ°¡ ÁÖ»ç ÀåÄ¡¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ´Â ¿äÀÎÀÔ´Ï´Ù.

ÀÇ·á Á¾»çÀÚ¿Í ±â¾÷ÀÌ ÀÚ°¡ÁÖ»ç±â¿Í °°Àº ÀÚ°¡ ÁÖ»ç ÀåÄ¡¸¦ µµÀÔÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹Ù´Ã¿¡ Âñ¸®´Â ºÎ»óÀ» ¹æÁöÇÏ´Â °ÍÀÔ´Ï´Ù. ¹Ì±¹, À¯·´ ¹× ±âŸ ½ÃÀå¿¡¼­´Â ÀÇ·á Á¾»çÀÚÀÇ ¹Ù´Ã¿¡ Âñ¸®´Â ºÎ»óÀ» ¹æÁöÇϱâ À§ÇØ ¾ÈÀü ÀåÄ¡ »ç¿ëÀ» Àǹ«È­Çϰí ÀÖ½À´Ï´Ù. ÀϺΠÀÚµ¿ ÁÖ»ç±â´Â ÀÇ·áÁø¿¡°Ô ¹Ù´Ã¿¡ Âñ¸®Áö ¾Ê´Â Ãß°¡ ÇýÅÃÀ» Á¦°øÇÕ´Ï´Ù. ¹Ì±¹¿¡¼­´Â ¿¬°£ ¾à 69,000°ÇÀÇ ºÎ»óÀ» ¿¹¹æÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸¹Àº ÀÚµ¿ ÁÖ»ç±â¿¡´Â ºÎ»ó À§ÇèÀ» Á¦°ÅÇϰųª ÁÙÀÌ´Â ÅëÇÕ ¹× ¼öµ¿ ¾ÈÀü ±â´ÉÀÌ ³»ÀåµÇ¾î ÀÖ½À´Ï´Ù.

»õ·Î¿î ¾à¹°Àü´Þ ½Ã½ºÅÛ(NDDDS) ºÐ¾ßÀÇ Çõ½ÅÀº ÀÚ°¡ Åõ¿© ¾à¹°¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¹Ì¸® ä¿öÁø ÁÖ»ç±â, ÆæÇü ÁÖ»ç±â, ÀÚµ¿ ÁÖ»ç±â, ¹«Ä§ ÁÖ»ç±â µî »õ·Î¿î ÁÖ»çÁ¦ Àü´Þ ÀåºñÀÇ ¹ß¸íÀº ȯÀÚÀÇ ¾à¹° ÀÚ°¡ Åõ¿©¸¦ ´õ¿í ½±°í Æí¸®ÇÏ°Ô ¸¸µé¾ú½À´Ï´Ù. ´ëºÎºÐÀÇ »ý¹°ÇÐÀû Á¦Á¦´Â Áֻ縦 ÅëÇØ Åõ¿©µÇ´Âµ¥, ÀÌ´Â ¹Ù´Ã¿¡ Âñ¸®´Â ¼Õ»óÀÇ À§ÇèÀÌ ÀÖ½À´Ï´Ù. ÀÌ ¹®Á¦¸¦ ÃÖ¼ÒÈ­Çϱâ À§ÇØ Á¦¾àȸ»ç´Â ÀÚ°¡ ÁÖ»ç ¹Ù´ÃÀÌ ÇÊ¿ä ¾ø´Â ÁÖ»ç±â ¹× ȯÀÚ Ä£È­ÀûÀÎ ¾à¹°°ú ±â±âÀÇ Á¶ÇÕ Á¦Ç°À» °³¹ßÇϰí ÀÖ½À´Ï´Ù.

COVID-19 ÆÒµ¥¹ÍÀº Åõ¾à ȯ°æ¿¡ ´ëÇÑ ±â´ë¿Í ÀνÄÀ» º¯È­½ÃÄÑ ÀÚ°¡ Åõ¾à¿¡ ´ëÇÑ ¼±È£µµ¸¦ ³ôÀÌ´Â µ¥ ÀÏÁ¶Çß½À´Ï´Ù. COVID-19 ¹é½ÅÀº ÁÖ»ç±â¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ̸ç, ÆÒµ¥¹ÍÀº ÀÚ°¡ »ç¿ë ¹× Ä¿³ØÆ¼µå µð¹ÙÀ̽ºÀÇ ÀÌÁ¡À» º¸¿©ÁÖ¾úÀ¸¸ç, ÀϺΠÁ¦Á¶¾÷üµéÀº ¾à¹°Àü´Þ ¼³°è¿¡¼­ ȯÀÚ °æÇèÀ» Áß¿äÇÑ ¿ä¼Ò·Î »ï´Â °æÇâÀÌ ÀÖ½À´Ï´Ù. ÆÒµ¥¹Í ÀÌÈÄ, ÇâÈÄ ±â±â Çõ½ÅÀÌ °¡¼ÓÈ­µÉ °ÍÀ¸·Î º¸À̸ç, Á¦¾à»çµéÀº ¾Û, ÀüÈ­, ÄÄÇ»ÅÍ µî ´Ù¸¥ µðÁöÅÐ ÀÚ»ê°ú ÇÔ²² ÀÚ°¡ ÁÖ»ç ±â±â¸¦ »ç¿ëÇϱâ À§ÇØ Á¡Â÷ÀûÀ¸·Î Çù·ÂÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ±Ã±ØÀûÀ¸·Î ȯÀÚ°¡ ÀÚ½ÅÀÇ Ä¡·á¸¦ ÈξÀ ´õ Àß ÅëÁ¦ÇÒ ¼ö ÀÖ°Ô µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ÀÚ°¡ÁÖ»ç±â ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • ½ÃÀåÀº Á¦Ç°º°·Î ÀÚµ¿ ÁÖ»ç±â, ÆæÇü ÁÖ»ç±â, ¿þ¾î·¯ºí ÁÖ»ç±â, ¹«Ä§ ÁÖ»ç±â µîÀ¸·Î ºÐ·ùµË´Ï´Ù. ¹«Ä§ ÁÖ»ç±â ºÐ¾ß´Â ³ôÀº È¿°ú¿Í ¼¼°è º¸±Þ·ü·Î ÀÎÇØ 2024³â ½ÃÀåÀÇ ¾à 28.32%¸¦ Â÷ÁöÇÏ¸ç °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • »ç¿ë¼º¿¡ µû¶ó ½ÃÀåÀº Àç»ç¿ë°ú ÀÏȸ¿ë ºÎ¹®À¸·Î ³ª´¹´Ï´Ù. ÀÏȸ¿ë ºÎ¹®Àº 2024³â ¾à 62.64%ÀÇ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀÔ´Ï´Ù.
  • ¿ëµµº°·Î ½ÃÀåÀº ¾Ï, ÅëÁõ °ü¸®, ÀÚ°¡¸é¿ªÁúȯ, È£¸£¸ó Áúȯ, ±âŸ·Î ºÐ·ùµË´Ï´Ù. ¾ÏÀº ÁÖ¿ä ºÎ¹® Áß Çϳª·Î 2021³â ½ÃÀå Á¡À¯À²Àº ¾à 26.82%¿´½À´Ï´Ù.
  • ºÏ¹Ì ÀÚ°¡ÁÖ»ç±â ½ÃÀåÀº 2024³â ¸ÅÃâ Á¡À¯À² 42.44%¸¦ Â÷ÁöÇϸç Àüü ¼¼°è ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ºÏ¹Ì ½ÃÀåÀº ÀÚ°¡ Ä¡·á¿¡ ´ëÇÑ È¯ÀÚ ¼±È£µµ Áõ°¡, ¾Ï ȯÀÚ Áõ°¡, È£¸£¸ó Áúȯ Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÚ°¡ÁÖ»ç±â ½ÃÀåÀº ÁÖ·Î Àεµ, Áß±¹, ÀϺ» µî ÁÖ¿ä ±¹°¡ÀÇ ÀÇ·á ÀÎÇÁ¶óÀÇ ±Þ¼ÓÇÑ ¹ßÀü°ú ¸¸¼ºÁúȯ Ä¡·á¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡·Î ÀÎÇØ Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ÀÚ°¡ÁÖ»ç±â ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óºÎ ½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ÀÚ°¡ÁÖ»ç±â ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå ÀÚ°¡ÁÖ»ç±â ½ÃÀå : Á¦Ç° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ÀÚ°¡ÁÖ»ç±â ½ÃÀå : Á¦Ç° º¯µ¿ ºÐ¼®
  • ÀÚ°¡ÁÖ»ç±â ½ÃÀå : Á¦Ç°º° Àü¸Á
  • 2018³âºÎÅÍ 2030³â±îÁö ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®
  • ¿ÀÅäÀÎÁ§ÅÍ
  • ÆæÇü ÁÖ»ç±â
  • ¿þ¾î·¯ºí ÀÎÁ§ÅÍ
  • ¹«¹Ù´Ã ÁÖ»ç±â

Á¦5Àå ÀÚ°¡ÁÖ»ç±â ½ÃÀå : »ç¿ë¼º ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ÀÚ°¡ÁÖ»ç±â ½ÃÀå : »ç¿ë¼º º¯µ¿ ºÐ¼®
  • »ç¿ë¼º Àü¸Á¿¡ ÀÇÇÑ ÀÚ°¡ÁÖ»ç±â ½ÃÀå
  • 2018³âºÎÅÍ 2030³â±îÁö ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®
  • ÀÏȸ¿ë
  • Àç»ç¿ë °¡´É

Á¦6Àå ÀÚ°¡ÁÖ»ç±â ½ÃÀå : ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ÀÚ°¡ÁÖ»ç±â ½ÃÀå : ¿ëµµ º¯µ¿ ºÐ¼®
  • ÀÚ°¡ÁÖ»ç±â ½ÃÀå ¿ëµµº° Àü¸Á
  • 2018³âºÎÅÍ 2030³â±îÁö ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®
  • ¾Ï
  • ÀÚ°¡¸é¿ªÁúȯ
  • ÅëÁõ °ü¸®
  • ±âŸ

Á¦7Àå ÀÚ°¡ÁÖ»ç±â ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ª ´ë½Ãº¸µå
  • Áö¿ªº° ÀÚ°¡ÁÖ»ç±â ½ÃÀå º¯µ¿ ºÐ¼®
  • ÀÚ°¡ÁÖ»ç±â ½ÃÀå : ±â¼ú°ú ÃÖÁ¾ ¿ëµµº° Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®
  • 2018³âºÎÅÍ 2030³â±îÁö ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
    • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦8Àå °æÀï ±¸µµ

  • ½ÃÀå ÁøÃâ ±â¾÷ ºÐ·ù
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • YPSOMED
    • BD
    • Gerresheimer AG
    • Antares Pharma, Inc.
    • Haselmeier AG
    • NuGen Medical Devices
    • Owen Mumford Ltd.
    • SHL Medical AG.
    • Pfizer, Inc.
    • Amgen Inc.
ksm 24.12.27

Self-injection Devices Market Growth & Trends:

The global self-injection devices market size is expected to reach USD 40.50 billion by 2030, registering a CAGR of 10.31% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing patient volume and rising prevalence of chronic diseases along with the high adoption of advanced drug delivery systems are factors estimated to surge the demand for self-injection devices.

Prevention of needlestick injury is a primary factor for healthcare professionals and companies to introduce self-injection devices such as autoinjectors. To avoid needlestick injuries to healthcare workers, the U.S., Europe, and other markets mandate the use of safety devices. Several auto-injectors provide the additional benefit of needlestick protection to healthcare professionals. It is expected that in the U.S. about 69,000 injuries can be prevented annually. Numerous auto-injectors have integral and passive safety features that eliminate or reduce the risk of injury.

Innovation in the field of New Drug Delivery Systems (NDDDS) has led to the rising demand for self-administered medications. The invention of novel injectable delivery devices such as pre-filled syringes, pen injectors, autoinjectors, and needle-free injectors has made the self-administration of drugs easier and more convenient for patients. The majority of biological drugs are delivered using injections, which include the threat of needlestick injuries. To minimize this issue, pharmaceutical firms are developing self-administered needle-free injectors and patient-friendly medication-device combination products.

The COVID-19 pandemic has altered expectations and perceptions of delivery settings and contributed to a rise in preference for self-administration medication. As this becomes the norm, several manufacturers are inclined to make the patient experience the vital component of drug delivery design. Significantly, the COVID-19 vaccines will increase the demand for injectable devices and the pandemic has also shown the benefit of self-use devices as well as connected devices. Post-pandemic there may be a rise in upcoming innovation in devices and pharma manufacturers will progressively collaborate to use self-injection devices in combination with other digital assets such as apps, phones, and personal computers. Eventually, this will bring the patient into far greater control of their care.

Self-injection Devices Market Report Highlights:

  • The market is classified by product into auto-injectors, pen injectors, wearable injectors, and needle-free injectors. The needle-free injector segment held the largest share, accounting for around 28.32% of the market in 2024, due to its high effectiveness and adoption rates worldwide.
  • Based on usability, the market is segmented into reusable and disposable. The disposable segment held around 62.64% market share in 2024.
  • The market is segmented by application into cancer, pain management, autoimmune disorders, hormonal disorders, and others. Cancer is among the leading segments, holding around 26.82% market share in 2021.
  • North America self-injection devices market dominated the overall global market and accounted for 42.44% of revenue share in 2024. The North American market is driven by several factors, including increased preference of the patients toward self-medication, increasing cancer cases, and rising cases of hormonal diseases.
  • The Asia Pacific self-injection devices market is experiencing substantial growth, primarily driven by rapidly advancing healthcare infrastructure in key countries such as India, China, and Japan, alongside increasing investments in treating chronic disorders.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. End-Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Application outlook
    • 2.2.3. End Use outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Self-injection Devices Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing preference for self-administration
      • 3.2.1.2. Rising prevalence of hormonal disorders
      • 3.2.1.3. Technological advancements
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Risk of Infection and Complications
  • 3.3. Self-injection Devices Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Self-injection Devices Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Self-injection Devices Market: Product Movement Analysis
  • 4.3. Self-injection Devices Market by Product Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Autoinjectors
    • 4.5.1. Autoinjectors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Pen injectors
    • 4.6.1. Pen injectors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Wearable injectors
    • 4.7.1. Wearable injectors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Needle-free injectors
    • 4.8.1. Needle-free injectors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Self-injection Devices Market: Usability Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Self-injection Devices Market: Usability Movement Analysis
  • 5.3. Self-injection Devices Market by Usability Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Disposable
    • 5.5.1. Disposable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Reusable
    • 5.6.1. Reusable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Self-injection Devices Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Self-injection Devices Market: Application Movement Analysis
  • 6.3. Self-injection Devices Market by Application Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Cancer
    • 6.5.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Autoimmune disorders
    • 6.6.1. Autoimmune disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Pain management
    • 6.7.1. Pain management Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Self-injection Devices Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Regional Self-injection Devices Market Movement Analysis
  • 7.3. Self-injection Devices Market: Regional Estimates & Trend Analysis by Technology & End-use
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.5. North America
    • 7.5.1. North America Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. U.S.
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement scenario
      • 7.5.2.5. U.S. Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Canada
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement scenario
      • 7.5.3.5. Canada Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. Mexico
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement scenario
      • 7.5.4.5. Mexico Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Europe
    • 7.5.6. Europe Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. UK
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement scenario
      • 7.5.7.5. UK Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Germany
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement scenario
      • 7.5.8.5. Germany Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. France
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Competitive Scenario
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement scenario
      • 7.5.9.5. France Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.10. Italy
      • 7.5.10.1. Key Country Dynamics
      • 7.5.10.2. Competitive Scenario
      • 7.5.10.3. Regulatory Framework
      • 7.5.10.4. Reimbursement scenario
      • 7.5.10.5. Italy Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.11. Spain
      • 7.5.11.1. Key Country Dynamics
      • 7.5.11.2. Competitive Scenario
      • 7.5.11.3. Regulatory Framework
      • 7.5.11.4. Reimbursement scenario
      • 7.5.11.5. Spain Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.12. Denmark
      • 7.5.12.1. Key Country Dynamics
      • 7.5.12.2. Competitive Scenario
      • 7.5.12.3. Regulatory Framework
      • 7.5.12.4. Reimbursement scenario
      • 7.5.12.5. Denmark Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.13. Sweden
      • 7.5.13.1. Key Country Dynamics
      • 7.5.13.2. Competitive Scenario
      • 7.5.13.3. Regulatory Framework
      • 7.5.13.4. Reimbursement scenario
      • 7.5.13.5. Sweden Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.14. Norway
      • 7.5.14.1. Key Country Dynamics
      • 7.5.14.2. Competitive Scenario
      • 7.5.14.3. Regulatory Framework
      • 7.5.14.4. Reimbursement scenario
      • 7.5.14.5. Norway Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement scenario
      • 7.6.2.5. Japan Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement scenario
      • 7.6.3.5. China Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement scenario
      • 7.6.4.5. India Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement scenario
      • 7.6.5.5. South Korea Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement scenario
      • 7.6.6.5. Australia Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement scenario
      • 7.6.7.5. Thailand Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement scenario
      • 7.7.2.5. Brazil Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement scenario
      • 7.7.3.5. Argentina Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Middle East & Africa
    • 7.8.1. Middle East & Africa Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement scenario
      • 7.8.2.5. South Africa Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement scenario
      • 7.8.3.5. Saudi Arabia Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement scenario
      • 7.8.4.5. UAE Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement scenario
      • 7.8.5.5. Kuwait Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Key Company Profiles
    • 8.2.1. YPSOMED
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. BD
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Gerresheimer AG
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Antares Pharma, Inc.
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Haselmeier AG
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. NuGen Medical Devices
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Owen Mumford Ltd.
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. SHL Medical AG.
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Pfizer, Inc.
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Amgen Inc.
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦